Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing Post-allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma Using Ibrutinib

NCT02869633 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.

NCT NCT02869633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02869633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing Post-allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma Using Ibrutinib
Lead sponsor
Vanderbilt-Ingram Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2016
Completion date
October 31, 2023
Enrollment
23 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

blastoid variant mantle cell lymphoma, recurrent chronic lymphocytic leukemia, recurrent follicular lymphoma, recurrent hodgkin lymphoma, recurrent mantle cell lymphoma, refractory chronic lymphocytic leukemia, refractory follicular lymphoma, refractory hodgkin lymphoma, refractory mantle cell lymphoma